CDRH names Jacobson acting director
Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane
Just weeks after the Center for Devices and Radiological Health announced that Dr. Bruce Burlington would be leaving his post as director in March, the agency named Elizabeth Jacobson as acting director. Food and Drug Administration Commissioner Dr. Jane Henney announced Burlingtons departure in January (SCAN 2/3/99) and appointed Jacobson as his temporary successor last month. Henney continues to seek a permanent replacement for the position.
Jacobson arrived at the FDAs Bureau of Radiological Health in 1975 as a research geneticist. She has held several scientific and management posts at the Bureau and the CDRH, including director of the Office of Science and Technology and deputy director for science at the CDRH. Jacobson has served as acting director at the CDRH once before, from December 1992 to February 1993.
Jacobson will begin her tenure as acting director on March 13, when Burlington leaves for a new post as head of regulatory affairs at Wyeth-Ayerst Pharmaceuticals in Philadelphia.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
